New Frontiers: Graft-Free Healing and ROCK Inhibitors

While standard treatments for Fuchs’ Endothelial Corneal Dystrophy (FECD) involve replacing diseased cells with a donor transplant, an emerging surgical approach is offering an alternative for a carefully selected group of early-stage patients. This procedure, known as Descemet Stripping Only (DSO)—sometimes called DWEK (Descemet stripping Without Endothelial Keratoplasty)—allows the eye to heal using its own cells ^[1][2].

The Concept: Healing From Within

In a traditional transplant, a surgeon replaces your failing endothelial “pumps” with those from a donor. In DSO, no donor tissue is used. Instead, the surgeon carefully removes only the central portion of your diseased Descemet membrane, which contains the most concentrated guttae ^[1][3].

• Migration: Once this central “patch” of diseased tissue is gone, the healthy endothelial cells in the outer (peripheral) edges of your cornea begin to enlarge and move inward ^[4].
• The Goal: These migrating cells spread out to cover the central area, potentially restoring your cornea’s ability to pump out fluid and maintain clarity ^[5].
• No Rejection: Because you are using your own cells, there is zero risk of donor graft rejection, and patients typically avoid the long-term steroid eye drops required for transplants ^[2][6]. However, DSO carries other ordinary surgical risks.

Accelerating the Process: ROCK Inhibitors

Many surgeons pair DSO with the use of ROCK inhibitors (Rho-kinase inhibitors), such as ripasudil or netarsudil, to help cells migrate faster toward the center of the cornea ^[7].

Important Note: The use of ROCK inhibitors for FECD and DSO is considered off-label or investigational in many jurisdictions, and evidence comes from relatively small, heterogeneous studies. Drug choice, dose, duration, and monitoring must be determined by your corneal specialist.

• Study Findings on Clearance: Small trials suggest ROCK inhibitors can speed recovery. In one review, eyes treated with a ROCK inhibitor cleared in an average of 4.9 weeks, compared to 10.1 weeks for those that healed on their own ^[8][9]. In a specific phase 2 trial, 81% of patients using ripasudil cleared their corneal swelling by 12 weeks, compared to 9% using a placebo ^[7]. These figures are study results, not guaranteed outcomes.
• The Regimen: The exact schedule will be prescribed by your surgeon, often involving multiple drops a day. Do not restart or change the frequency of a ROCK inhibitor without your doctor’s instructions.

Is DSO Right for You? (Selection Criteria)

DSO is a highly selective surgery that is not suitable for everyone. Surgeons often look for approximate factors such as:

1. Centralized Disease: Guttae should be concentrated in the center of your eye, with a “reservoir” of healthy, clear cells in the periphery ^[10][8].
2. Healthy Cell Count: Some surgeons use a peripheral endothelial cell count of 1,000 to 1,500 cells/mm² as a guideline to ensure there are enough healthy cells to migrate, though this is not a universally validated cutoff ^[11][12].
3. Mild Swelling: DSO is best suited for those with early-stage disease. If your entire cornea is already severely swollen, your peripheral cells may not repopulate the center successfully ^[8][13].

The Recovery and Rescue Plan

It is vital to understand that your vision will get worse before it gets better. Unlike a DMEK transplant, which can offer clarity in weeks, DSO has a longer “cloudy” phase ^[2].

• The Fog: Immediately after surgery, your central cornea will be very swollen because the “pumps” in that area have been removed. This creates a period of very blurry vision that typically lasts several weeks ^[14][2].
• Inadequate Clearing: DSO does not work for everyone. The failure rate depends heavily on patient selection (roughly estimated near 10% in some studies) ^[15]. Failed or inadequate clearing is managed individually. If your cornea does not clear or swelling worsens, your surgeon can perform a “rescue” DMEK transplant to provide the donor cells your eye needs ^[16].

Potential Side Effects

ROCK inhibitors can cause temporary side effects such as:

• Eye Redness: A very common but harmless “flush” of the eye ^[11].
• Reticular Edema: A specific, honeycomb-like pattern of temporary swelling on the surface of the eye that usually disappears once you stop the drops ^[4][17].
• Recurrence: In some cases, swelling can return. While it sometimes clears after restarting drops, recurrence may not respond to drops and might eventually require a DMEK ^[11].